Krystal Biotech, Inc. (KRYS) Income Statement Analysis

See more : Win Win Precision Technology Co., Ltd. (4949.TW) Income Statement Analysis – Financial Results

Complete financial analysis of Krystal Biotech, Inc. (KRYS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Krystal Biotech, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

M Pictures Entertainment Public Company Limited (MPIC.BK) Income Statement Analysis – Financial Results
Blackrock Oil Corporation (ONTRF) Income Statement Analysis – Financial Results
SkinBioTherapeutics Plc (SBTX.L) Income Statement Analysis – Financial Results
Montfort Capital Corp. (MONT.V) Income Statement Analysis – Financial Results
PT Midi Utama Indonesia Tbk (MIDI.JK) Income Statement Analysis – Financial Results

Krystal Biotech, Inc. (KRYS)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.krystalbio.com

About Krystal Biotech, Inc.

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Metric	2023	2022	2021	2020	2019	2018	2017	2016
Revenue	50.70M	0.00	0.00	0.00	0.00	1.03M	0.00	0.00
Cost of Revenue	3.09M	4.05M	2.77M	1.85M	974.00K	141.00K	23.00K	2.00K
Gross Profit	47.61M	-4.05M	-2.77M	-1.85M	-974.00K	886.00K	-23.00K	-2.00K
Gross Profit Ratio	93.90%	0.00%	0.00%	0.00%	0.00%	86.27%	0.00%	0.00%
Research & Development	46.43M	42.46M	27.88M	17.94M	15.62M	7.76M	3.21M	741.00K
General & Administrative	0.00	77.74M	40.39M	15.06M	6.47M	4.16M	1.56M	402.00K
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	98.40M	77.74M	40.39M	15.06M	6.47M	4.16M	1.56M	402.00K
Other Expenses	12.50M	25.00M	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	157.33M	120.20M	68.28M	33.00M	22.08M	11.92M	4.77M	1.14M
Cost & Expenses	147.93M	120.20M	68.28M	33.00M	22.08M	11.92M	4.77M	1.14M
Interest Income	22.62M	5.22M	197.00K	832.00K	2.99M	0.00	0.00	0.00
Interest Expense	0.00	5.22M	1.49M	0.00	0.00	1.03M	3.15M	7.00K
Depreciation & Amortization	5.01M	4.05M	2.77M	1.85M	974.00K	141.00K	23.00K	2.00K
EBITDA	17.90M	-145.20M	-65.31M	-30.32M	-18.11M	-10.75M	-4.63M	-1.14M
EBITDA Ratio	35.31%	0.00%	0.00%	0.00%	0.00%	-1,146.54%	0.00%	0.00%
Operating Income	-109.73M	-145.20M	-68.28M	-33.00M	-22.08M	-11.92M	-4.77M	-1.14M
Operating Income Ratio	-216.43%	0.00%	0.00%	0.00%	0.00%	-1,160.27%	0.00%	0.00%
Total Other Income/Expenses	122.62M	5.22M	-1.30M	832.00K	2.99M	1.03M	-3.15M	-7.00K
Income Before Tax	12.90M	-139.98M	-69.57M	-32.17M	-19.09M	-10.89M	-7.92M	-1.15M
Income Before Tax Ratio	25.44%	0.00%	0.00%	0.00%	0.00%	-1,060.27%	0.00%	0.00%
Income Tax Expense	1.97M	34.05M	2.73M	1.64M	576.14K	-20.14K	0.00	0.00
Net Income	10.93M	-139.98M	-69.57M	-32.17M	-19.09M	-10.89M	-7.92M	-1.15M
Net Income Ratio	21.56%	0.00%	0.00%	0.00%	0.00%	-1,060.27%	0.00%	0.00%
EPS	0.40	-5.49	-3.13	-1.71	-1.20	-0.97	-1.48	-0.27
EPS Diluted	0.39	-5.49	-3.13	-1.71	-1.20	-0.97	-1.48	-0.27
Weighted Avg Shares Out	27.15M	25.49M	22.20M	18.79M	15.90M	11.20M	5.36M	4.28M
Weighted Avg Shares Out (Dil)	27.75M	25.49M	22.20M	18.79M	15.90M	11.20M	5.36M	4.28M

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

March 14, 2024seekingalpha.com

Alpha-1 antitrypsin deficiency, or AATD, is an inherited disease that affects the lung, liver, and skin. The current treatment landscape involves smoking cessation, COPD treatment, and augmentation therapy with AAT. Newer therapies in development include elastase inhibitors, novel augmentation therapy,...

Krystal Biotech, Inc. (KRYS) Is a Great Choice for 'Trend' Investors, Here's Why

March 14, 2024zacks.com

If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech, Inc. (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Can Krystal Biotech, Inc. (KRYS) Run Higher on Rising Earnings Estimates?

March 8, 2024zacks.com

Krystal Biotech, Inc. (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Krystal Biotech, Inc. (KRYS) is a Great Momentum Stock: Should You Buy?

March 8, 2024zacks.com

Does Krystal Biotech, Inc. (KRYS) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Krystal Biotech, Inc. (KRYS) a New Buy Stock

March 8, 2024zacks.com

Krystal Biotech, Inc. (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years

March 1, 2024fool.com

These two mid-cap biotechs have exciting pipelines. Important breakthroughs could lead to market-beating returns.

Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference

February 28, 2024globenewswire.com

PITTSBURGH, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the TD Cowen 44th Annual Health Care Conference, which takes place in Boston on...